Advancements in Precision Medicine for Prostate and Urothelial Cancer

Advancements in Precision Medicine for Prostate and Urothelial Cancer

Introduction:
In recent years, significant progress has been made in understanding and treating aggressive variants of prostate cancer and urothelial carcinoma. With the advent of precision medicine, the focus has shifted towards tailoring therapies based on individual molecular characteristics. This article explores the highlights from two conferences, APCCC 2019 and EAU 2020, where experts discussed the diagnosis and treatment of neuroendocrine prostate cancer and the importance of sequencing all urothelial cancer patients.

Neuroendocrine Prostate Cancer Spectrum - Diagnosis and Treatment:
At APCCC 2019, Dr. Efstathiou discussed the challenges in diagnosing and treating aggressive variant prostate cancer. Previously, the first-line treatment was based solely on clinical criteria, resulting in varied recommendations. However, Dr. Efstathiou's research showed that adding carboplatin to cabazitaxel improved progression-free survival in at-risk men. The clinicopathologic criteria for aggressive variant prostate cancer were outlined, including small cell prostate carcinoma, visceral metastases, lytic bone metastases, bulky nodes or prostate mass, low PSA relative to disease volume, elevated neuroendocrine markers, and primary castration-resistance. The terminology used to describe this variant was also discussed, with "AR negative prostate cancer" being considered too limiting.

Perioperative Therapy for Urothelial Cancer: Should We Sequence All Urothelial Cancer Patients?
The discussions at EAU 2020 focused on the importance of personalized treatment for urothelial carcinoma. The understanding that urothelial carcinoma is a highly heterogeneous disease, driven by different molecular defects, has paved the way for precision medicine. It was emphasized that selecting the right therapy for the right tumor in the right patient at the right time is crucial. The prevalence of mutations in urothelial carcinoma suggests that all patients with metastatic disease should undergo testing. The identification of key urothelial cancer genes, such as MMR, FGFR, and DNA repair, has further enhanced the potential for biomarker-driven therapy.

Connecting the Dots:
Both conferences shed light on the importance of molecular characteristics in guiding treatment decisions. In the case of aggressive variant prostate cancer, the identification of clinicopathologic criteria helps in diagnosing and treating this aggressive subtype. The terminology used to describe this variant is still under debate, highlighting the need for a standardized nomenclature. Similarly, in urothelial carcinoma, the understanding of different molecular defects has opened up opportunities for precision medicine. The identification of specific genes and the availability of commercial tests have implications for both patients and their families.

Actionable Advice:

1. Incorporate Molecular Testing: For patients with metastatic urothelial carcinoma and aggressive variant prostate cancer, molecular testing should be considered to identify potential therapeutic targets. This can guide treatment decisions and improve outcomes.

2. Collaboration between Clinicians and Researchers: The field of precision medicine is rapidly evolving, and it is essential for clinicians and researchers to collaborate and stay updated on the latest advancements. This can ensure that patients receive the most effective and personalized treatments available.

3. Education and Awareness: Patients and their families should be educated about the importance of molecular testing and the implications it may have on treatment options and prevention strategies. Increased awareness can lead to improved outcomes and better overall management of these cancers.

Conclusion:
The advancements in precision medicine have revolutionized the diagnosis and treatment of aggressive variants of prostate cancer and urothelial carcinoma. The integration of molecular characteristics into clinical decision-making offers a more personalized approach to therapy. However, further research and collaboration are required to optimize the use of biomarker-driven therapy. By incorporating molecular testing, promoting collaboration, and increasing education and awareness, we can continue to improve patient outcomes and pave the way for advancements in precision medicine.